Skip to content

Simplification

In less than one year we successfully completed the deconsolidation of Fresenius Medical Care – a landmark of our #FutureFresenius agenda.

Read more

Focus

We place a clear focus on our “Operating Companies” Fresenius Kabi and Fresenius Helios – both have attractive market positions and excellent opportunities for profitable growth.

Read more

Performance

We increased financial transparency, exceeded our structural productivity targets, and made an important paradigm shift in how we measure our performance.

Read more

Financial Highlights

We achieved the raised outlook for 2023 and had a strong finish to the year with continued good development of our Operating Companies Fresenius Kabi and Fresenius Helios and progress in the turnaround of our Investment Company Fresenius Vamed.

To Group financial figures
  • GROUP REVENUE

    20,000m

    +6%1

    FY/22: €21,532m2

  • GROUP EBIT3

    2,000m

    +2%4

    FY/22: €2,190m2

  • OPERATING CASHFLOW

    2,000m

    +5%

    FY/22: €2,031m2

  • KABI REVENUE

    7,500m

    +7%1,5

    FY/22: €7,850m

  • HELIOS REVENUE

    10,000m

    +5%1

    FY/22: €11,716m

  • VAMED REVENUE

    2,000m

    +1%1,6

    FY/22: €2,359m

1 Organic growth​
2 Prior-year figures have been adjusted due to the application of IFRS 5 to the deconsolidated operations of Fresenius Medical Care.
3 Before special items
4 At constant currency
5 To show the underlying business development, the organic growth definition was adjusted to fully exclude the significant inflation accounting effects in Argentina.
6 From continued operations

Letter to our shareholders

For Fresenius, 2023 was a year of change and new beginnings. We successfully launched our #FutureFresenius corporate strategy and set the course for profitable growth.

Read more

Strategy

In the 2023 fiscal year, we successfully advanced our strategy #FutureFresenius in order to transform our Group and position it for the future.

Read more